Seroquel News and Research

RSS

Seroquel is a drug approved to treat acute depressive episodes in bipolar disorder; acute manic or mixed episodes in bipolar disorder alone or when added to lithium or divalproex; long-term maintenance of bipolar disorder when added to lithium or divalproex; and schizophrenia.

Antidepressants are not designed for dementia, shows study

Nearly three-quarters of older adults with dementia have filled prescriptions for medicines that act on their brain and nervous system, but aren't designed for dementia, a new study shows.

19 Aug 2020

Common medications can masquerade as dementia in seniors

By all accounts the woman, in her late 60s, appeared to have severe dementia. She was largely incoherent. Her short-term memory was terrible. She couldn't focus on questions that medical professionals asked her.

18 Jul 2019

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

In the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson's disease psychosis -- a symptom of the progressive nervous system disorder in which patients experience hallucinations and delusions -- researchers at University of California San Diego School of Medicine conducted a retrospective study of qualifying patients in the UC San Diego Health system, concluding that the new drug, pimavanserin, did not pose a statistically significant greater risk of death.

27 Sep 2018

Peer comparison letters lead to persistent decrease in antipsychotic prescribing

A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel, an antipsychotic with potentially harmful side effects in the elderly, significantly reduced the number of prescriptions for patients in Medicare.

2 Aug 2018

Lithium treatment associated with lowest risk of rehospitalization for bipolar disorder patients

Individuals with bipolar disorder have the lowest risk of rehospitalization if treated with lithium, according to a study from Karolinska Institutet in Sweden published in JAMA Psychiatry. Long-acting injections of antipsychotics were also effective, reducing the risk of rehospitalization by 30 percent compared with their oral counterparts.

28 Feb 2018

Former pharma reps’ new mission: To school docs on high drug costs

As a drug salesman, Mike Courtney worked hard to make health care expensive. He wined and dined doctors, golfed with them and bought lunch for their entire staffs — all to promote pills often costing thousands of dollars a year.

8 Jun 2017

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Nine in 10 primary care physicians say that prescription drug abuse is a moderate or big problem in their communities and nearly half say they are less likely to prescribe opioids to treat pain compared to a year ago, new Johns Hopkins Bloomberg School of Public Health research suggests.

9 Dec 2014

State highlights: Md., Minn. see small business health insurance rate changes; Texas sues AstraZeneca over Seroquel marketing

Some small businesses in Maryland will see a small drop in health insurance premiums next year, while others will pay as much as 11 percent more to cover their workers, according to rates released by state regulators Friday. The rates, which go into effect in January, only apply to small firms with up to 50 employees, and not to large or self-insured firms or individuals buying coverage on the state's health insurance exchange. Evergreen Health Cooperative sought no rate increase, and Aetna Health Inc. will raise rates only slightly, according to the rate information released by the Maryland Insurance Administration. Some UnitedHealthcare premiums will drop by about 2.5 percent (Cohn, 10/10).

14 Oct 2014

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications - schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs.

28 Nov 2012

Par to acquire Handa's ANDA for generic Seroquel XR

Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals, LLC to acquire Handa's Abbreviated New Drug Application (ANDA) for quetiapine fumarate extended-release tablets, the generic version of AstraZeneca's Seroquel XR.

29 Oct 2012

AstraZeneca first quarter revenue down 11% to $7,349 million

First quarter results reflect challenging revenue picture. Pipeline strengthened by Amgen collaboration, the agreement to acquire Ardea Biosciences and positive CHMP opinion for FORXIGATM (dapagliflozin) in Europe.

26 Apr 2012

Mylan receives FDA approval for generic Seroquel ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quetiapine Fumarate Tablets, 25 mg.

29 Mar 2012

Dr. Reddy’s introduces Quetiapine fumarate tablets in the U.S.

Dr. Reddy's Laboratories announced today that it has launched Quetiapine fumarate tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg), a bioequivalent generic version of SEROQUEL tablets in the US market on March 27, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Quetiapine fumarate tablets.

28 Mar 2012

AstraZeneca's lawsuit against FDA dismissed without prejudice

AstraZeneca today announced that on March 23, 2012 the US District Court for the District of Columbia issued an opinion and order in AstraZeneca's lawsuit against the US Food and Drug Administration regarding final marketing approval of generic quetiapine. The Court denied the Company's request for a preliminary injunction and dismissed the lawsuit without prejudice.

26 Mar 2012

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

12 Mar 2012

Weight gain or loss may also depend on medicines taken

Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking.

22 Feb 2012

Genetic variation predisposes children to complications linked with second-generation anti-psychotics

Researchers have found a genetic variation predisposing children to six-times greater risk of developing metabolic syndrome when taking second-generation anti-psychotic medications. Metabolic syndrome is a cluster of conditions that are risk factors for cardiovascular disease.

25 Jan 2012

First Edition: October 24, 2011

Today's headlines include a variety of health policy news developments, including speculation about how the Supreme Court might review the health law and what's happening with the super committee.

24 Oct 2011

AstraZeneca settles SEROQUEL XR patent infringement litigation

AstraZeneca today announced it has entered into a settlement agreement in its U.S. SEROQUEL XR patent infringement litigation against Handa Pharmaceuticals, LLC regarding Handa's proposed generic version of AstraZeneca's SEROQUEL XR extended-release tablets.

30 Sep 2011

Nurofen mix up with Seroquel schizophrenia drug warns MHRA

British drug regulators have issued a safety alert on Thursday after discovering packs of the over-the-counter painkiller Nurofen Plus containing the anti-psychotic drug Seroquel XL.

26 Aug 2011